MariTide and maridebart cafraglutide: trials, results, and status.
Also searched as maridebart cafraglutide · AMG 133
MariTide is Amgen’s investigational peptide-antibody conjugate for obesity and related conditions. The useful story is not “a quarterly weight-loss shot” yet: monthly treatment has the clearest efficacy record, while quarterly dosing has been studied as continued maintenance treatment.
Will MariTide be monthly or quarterly?
Monthly treatment has the clearest published efficacy record. Quarterly dosing has been studied as continued lower-frequency maintenance in selected participants after substantial weight loss. That does not establish a quarterly starting schedule, a future approved dose, or an available commercial medicine.
Compare MariTide with Retatrutide, without losing the country context.
Put evidence status, ClinicalTrials.gov coverage, official United States records, and qualified US research prices in one view. Blank fields stay blank when the underlying dataset does not support a number.
Investigational clinical program
Official product and seller records attached
Investigational clinical program
What can you conclude about MariTide today?
These are dated program facts, not a cross-trial ranking, approval forecast, personal treatment recommendation, or proof that a same-name online product is the sponsor's medicine.
Amgen’s 52-week Phase 2 program studied monthly or less-frequent subcutaneous dosing.
Mean loss at week 52 under the efficacy estimand in participants without diabetes; the treatment-policy range was 12.3%–16.2%.
Lower monthly or quarterly doses were continued during a second treatment year in selected Phase 2 participants.
MARITIME studies include chronic weight management and obesity-related conditions.
Know which molecule the result belongs to.
- Sponsor
- Amgen
- Mechanism
- GLP-1 receptor agonist + GIP receptor antagonist
- Route being studied
- Subcutaneous injection
- Current stage
- Phase 3 program active
- Featured trial anchors
- NCT05669599 · NCT06858878 · NCT07037433
- Evidence checked
- July 20, 2026
MariTide weight-loss results, with the trial attached.
This visual shows one selected result, not every dose or endpoint in the program. The percentage remains attached to its duration, population, comparator, analysis method, and source.
Evidence checked July 21, 2026MariTide reported 19.9% mean reduction at 52 weeks under the efficacy estimand, upper end of the reported dose-group range. The comparator recorded 2.6% mean reduction.
Bar lengths share a 0 to 30% visual scale. They describe this selected record and do not make separate trials head-to-head.
- Population
- Adults with obesity or overweight, without type 2 diabetes
- Participants
- 465 Cohort A; 592 adults were enrolled across cohorts A and B
- Dose
- Upper reported dose-group result
- Primary analysis
- Efficacy estimand, upper end of the reported dose-group range
- Alternate analysis
- Treatment-policy estimand, upper end of the reported dose-group range
- Regulatory status
- Investigational; not FDA approved
MariTide clinical trials by status, phase, and location.
The current exact-intervention snapshot matches 27 unique NCT records. This chart describes registry coverage and current study fields. It does not compare efficacy, safety, approval probability, eligibility, or treatment access.
Snapshot 2026-07-24Counts use individual locations currently marked Recruiting, not every facility listed on an overall-recruiting study. Repeated centers across studies remain repeated site observations.
What comes after Retatrutide?
Compare Zenagamtide/Amycretin, MariTide, CagriSema, standalone cagrilintide, and survodutide by route, evidence maturity, trial result, and approval status without ranking unrelated studies as one race.
Open the upcoming weight-loss drugs guide →MariTide across 42 countries.
This profile establishes the program identity and its cited clinical or regulatory record. It does not turn a same-name seller listing into the sponsor’s asset or prove authorization, availability, or lawful supply in another destination.
Compare MariTide by country →Compare MariTide by US state →Browse the global peptide country dataset →Is MariTide approved or available in your country?
Start with the United States FDA record, then check the destination that matters to you. Each country page separates drug identity, authorization, product records, seller claims, and supply rules. Directory checked July 20, 2026.
What the record shows - and what it doesn’t.
Trial percentages are kept beside the design details that make them interpretable. Unknowns stay visible instead of being filled with launch speculation.
Monthly Phase 2 efficacy
Amgen reported mean weight change of 16.3%–19.9% at week 52 under an efficacy estimand and 12.3%–16.2% under a treatment-policy estimand in the obesity cohort without diabetes. Those are different statistical questions and should not be collapsed into one universal result.
Quarterly maintenance was studied
In the exploratory second year, participants who had lost at least 15% in year one were re-randomized to continued treatment or placebo. Amgen reported that a large majority maintained the prior loss while receiving a lower monthly or quarterly dose. This was continued dosing, not evidence that weight remained off after stopping.
A broad Phase 3 program exists
ClinicalTrials.gov records document Phase 3 studies in chronic weight management, type 2 diabetes with overweight or obesity, cardiovascular outcomes, heart failure, and obstructive sleep apnea. Individual records have different enrollment states and completion dates.
No approval or commercial schedule
MariTide is not an FDA-approved obesity medicine. A final label, approved dose, launch timing, price, insurance coverage, and pharmacy availability do not exist yet.
Quarterly initiation is not established
The cited quarterly result concerns maintenance after substantial prior loss and continued treatment. It does not establish that patients would begin treatment with one injection every three months.
Stopping-treatment durability is unresolved
The sponsor sources cited here do not show that people broadly maintained weight loss for months after discontinuing MariTide. Continued low-frequency dosing and stopping treatment are different claims.
The questions behind the search.
Concise answers based on the dated sponsor and trial records below. This is educational reporting, not medical advice.
What is MariTide and how does it work?
MariTide is the development name for maridebart cafraglutide, formerly AMG 133. Amgen describes it as a long-acting peptide-antibody conjugate that activates the GLP-1 receptor while antagonizing the GIP receptor. It is administered under the skin in trials and is being studied for obesity, type 2 diabetes, and several obesity-related conditions. It remains investigational, so this mechanism and trial schedule should not be read as an approved indication or dosing instruction.
Is MariTide a monthly or quarterly injection?
Monthly dosing has the clearest published efficacy evidence. Quarterly dosing appeared in an exploratory second-year maintenance study among selected participants who first achieved at least 15% weight loss during the 52-week Phase 2 study. They continued on lower monthly or quarterly MariTide doses. That makes quarterly maintenance an important research direction, but it does not establish a quarterly starting regimen or a future approved schedule.
Did people keep the weight off after stopping MariTide?
That claim is not supported by the sponsor records cited on this page. Amgen’s second-year update says many participants maintained their prior weight loss while receiving continued lower monthly or quarterly treatment. A placebo group was also part of the exploratory design, but the sponsor summary does not justify a broad claim that weight loss persisted for months after treatment stopped. The careful takeaway is continued low-frequency maintenance, not proven off-treatment durability.
Do not use an investigational name, trial dose, or online research listing as a substitute for approved care. This page does not recommend treatment, sourcing, or participation in a clinical trial.
Understand the product-category boundary →